Semaglutide Before and After 1 Month: Results and What to Expect
Carson @ Eden
Weight Loss
10 min read
Get a detailed breakdown of what to expect after one month on semaglutide, including weight loss results, side effects, and expert tips to enhance your progress.
Key takeaways
Semaglutide functions as a GLP-1 receptor agonist, aiding in weight management and T2 diabetes management.
It may reduce cardiovascular events risk by 20% in adults with obesity [2].
It may Lower blood sugar levels and promote insulin production [3].
It may decrease appetite.
The medication may work by mimicking natural GLP-1 hormones, enhancing insulin secretion while suppressing glucagon release.
For optimal results, patients should combine semaglutide with lifestyle modifications, including a healthy diet and regular exercise.
The medication is typically administered as a weekly injection, with dosage carefully adjusted over time, as prescribed by your licensed healthcare provider.
Semaglutide is a medication which may support weight management goals when combined with lifestyle changes such as diet and exercise. While individual results may vary, understanding outcomes of semaglutide from current or past users may help understand timing.
For those considering this medication, the first month on semaglutide may mark a period of adjustments and initial results. This article examines results of semaglutide with a focus on what new users may expect during their first month of treatment.
Semaglutide is an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management. It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1). It works by mimicking a natural hormone that helps regulate appetite and blood sugar levels [3].
Semaglutide may operate through multiple pathways to promote weight management and metabolic health:
It may target brain centers controlling appetite regulation
It slows gastric emptying for prolonged satiety
It enhances insulin secretion while suppressing glucagon release
The medication may be available in different FDA-approved formulations, such as Wegovy® for weight management and Ozempic® for diabetes treatment [5]. It may also be available as compounded semaglutide. Please note that compounded medications are not approved by the FDA for safety, effectiveness, or quality.
When used as prescribed, semaglutide has demonstrated approximately 15% reduction in initial weight over 68 weeks [6].
Semaglutide for Weight Management: What You Need to Know
Studies show that patients using semaglutide 2.4 mg had an average weight loss of 14.9% over 68 weeks, compared to 2.4% in the placebo group [8]. The medication may be available for chronic weight management in adults who meet certain criteria:
BMI of 30 kg/m² or greater (obesity), or
BMI of 27 kg/m² or greater (overweight) with at least one weight-related condition
Used in conjunction with a reduced-calorie diet and increased physical activity
In long-term studies, 77.1% of patients achieved 5% or more weight loss at 104 weeks, compared to 34.4% in the placebo group [9]. The study showed sustained loss for up to 4 years with proper use [10].
The medication may work best when combined with lifestyle modifications, making it a tool rather than a standalone solution for weight management [8].
Semaglutide Before and After: How Much Weight Loss Can You Expect After One Month?
Studies show that patients may lose more than 2% of their body weight in the first 4 weeks of using semaglutide [11]. The STEP 1 trial reported an average weight loss of 3.8% after 4 weeks on the 2.4 mg dose [12].
Initially, most patients may expect weight loss ranging from 2-5 pounds in the first month [13]. It's important to note that this initial decrease may come from:
Fluid loss
Changes in appetite and eating patterns
Potential gastrointestinal adjustments
Metabolic adaptations
One documented case showed progress with lifestyle modifications, reaching their goal weight through gradual, sustainable loss [14]. Another patient reported losing approximately 5 pounds per month, achieving a total of 15 pounds lost after three months [15].
Results may vary among individuals.
Physical Changes You Might See After One Month of Semaglutide Treatment
The physical transformation during the first month of semaglutide treatment may extend beyond numbers on the scale. Reviews show that patients may experience measurable changes in body composition and physical measurements during this initial period.
Physical changes previously observed after one month include:
Reduction in waist circumference
Changes in body mass index (BMI)
Improvements in overall body composition
Changes in clothing fit
Studies showing an average reduction in waist circumference of 7.7 cm over time [10]. 52.4% of patients achieved improvement in their BMI category by week 104.
Individual responses may vary based on several factors, including age and initial body weight.
Semaglutide Side Effects: What to Expect in the First Month
Understanding potential side effects is important for patients beginning their semaglutide journey. Medical research indicates that gastrointestinal effects are t reported reactions during the initial treatment phase [17].
To manage nausea from semaglutide, and other side effects, patients may consider eating smaller meals and avoiding foods that may trigger discomfort. Studies show that following specific dietary recommendations may reduce symptom intensity [17].
Factors That Impact Your Results After One Month on Semaglutide
Factors may influence a patient's response to semaglutide treatment during the initial month.
How Semaglutide Doses Change Over Time
Patients may begin with 0.25mg weekly for the first month, gradually increasing to the maximum dose of semaglutide of 2.4mg over several months [18], as prescribed by your licensedh healthcare provider.
Research indicates that patients receiving higher doses had a 12.1% mean weight loss at six months compared to 9.2% for those on lower doses [19].
Semaglutide: How Diet and Lifestyle Boost Results
For sustainable results, you may combine semaglutide with lifestyle modifications such as diet and exercise such as maintaining:
Approximately 150 minutes of weekly physical activity
Protein intake of approximately 15% of total calories
Regular meal planning and preparation
The STEP program revealed that patients following these guidelines alongside medication achieved improvements in various health markers, including waist circumference and blood pressure [18].
How Metabolism and Personal Factors Affect Your Weight Loss
Research reveals that individual metabolic characteristics may influence semaglutide treatment outcomes, revealing who should and should not take semaglutide.
Several metabolic and personal factors may influence semaglutide effectivenes such as:
Age and baseline weight
Presence of diabetes and its severity
Concurrent medications, especially insulin
Individual metabolic rate
Hormonal balance
Setting Realistic Expectations for Semaglutide in the Short Term
Expectations for the first month may include:
Changes in appetite and satiety levels
Gradual adjustment to the medication
Individual response variations based on personal factors
Results will vary within individuals, and you should consult your healthcare provider for any questions. Semaglutide alongside diet and exercise may helps ensure sustainable progress toward long-term weight management goals [10].
Semaglutide Results After One Month: What's Next?
Research demonstrates that users may achieve 15.2% reduction from baseline at week 104 [25].
Tips to Maximize Your Semaglutide Results
Semaglutide alongside nutrition and exercise may prolong weight management results [26].
For optimal results, it is suggested to:
Consume smaller, frequent meals throughout the day
Practice mindful eating and slow consumption
Focus on nutrient-dense, whole foods
Maintain hydration with at least 80 ounces of water daily
Limit or avoid alcohol consumption
Rotate injection sites weekly between thighs, abdomen, and upper arms
Questions to Ask Your Doctor About Semaglutide
Preparing for a medical consultation about semaglutide requires careful consideration of various health factors.
Essential questions patients may discuss with their healthcare provider include:
Current medications and supplements being taken [31]
Personal and family medical history
Previous weight loss attempts
Pregnancy plans or current pregnancy status
Insurance coverage and cost considerations
Patients should discuss the frequency of follow-up appointments and necessary medical tests. Healthcare providers may order tests to monitor body responses to semaglutide treatment.
Final Thoughts
Semaglutide may offer a tool for achieving metabolic health goals. Semaglutide may show results when used alongside proper diet and exercise. Patients should remember that individual results may vary based on personal factors, including metabolism, age, and existing health conditions.
The medication may be used as part of a comprehensive weight management strategy rather than a standalone solution. Success may require patience, consistent adherence to prescribed protocols, and realistic expectations about the gradual nature of healthy weight management.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
Chao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2022). Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations. In Drug design, development and therapy (Vol. 16, pp. 4449–4461). Drug design, development and therapy. https://doi.org/10.2147/DDDT.S365416
Fornes, A., Huff, J., Pritchard, R. I., & Godfrey, M. (2022). Once-Weekly Semaglutide for Weight Management: A Clinical Review. In The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians (Vol. 38, Issue 4, pp. 239–246). The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians. https://doi.org/10.1177/87551225221092681
Ghusn, W., Rosa, A. D. la, Sacoto, D., Cifuentes, L., Campos, A., Feris, F., Hurtado, M. D., & Acosta, A. (2022). Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. In JAMA network open (Vol. 5, Issue 9, pp. e2231982–e2231982). JAMA network open. https://doi.org/10.1001/jamanetworkopen.2022.31982
Gorgojo-Martnez, J. J., Mezquita-Raya, P., Carretero-Gmez, J., Castro, A., Cebrin-Cuenca, A., Torres-Snchez, A. de, Garca-de-Lucas, M. D., Nez, J., Obaya, J. C., Soler, M. J., Grriz, J. L., & Rubio-Herrera, M. ngel. (2022). Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. In Journal of clinical medicine (Vol. 12, Issue 1, p. 145). Journal of clinical medicine. https://doi.org/10.3390/jcm12010145
Jakicic, J. M., Leonard, S., Amaro, A., Gilden, A., Moore, M., Chao, A. M., Wadden, T. A., & Tronieri, J. S. (2023). The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities. In Curr Obes Rep (Vol. 12, Issue 4). Springer. https://doi.org/10.1007/s13679-023-00534-z
Mahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2022). Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. In Reviews in endocrine & metabolic disorders (Vol. 23, Issue 3, pp. 521–539). Reviews in endocrine & metabolic disorders. https://doi.org/10.1007/s11154-021-09699-1
Ryan, D. H., Lingvay, I., Deanfield, J., Kahn, S. E., Barros, E., Burguera, B., Colhoun, H. M., Cercato, C., Dicker, D., Horn, D. B., Hovingh, G. K., Jeppesen, O. K., Kokkinos, A., Lincoff, A. M., Meyhfer, S. M., Oral, T. K., Plutzky, J., van Beek, A. P., Wilding, J. P. H., & Kushner, R. F. (2024). Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. In Nature Medicine (Vol. 30, Issue 7, pp. 2049–2057). Springer Science and Business Media LLC. https://doi.org/10.1038/s41591-024-02996-7
De la Rosa, A., Sacoto, D., Cifuentes, L., Campos, A., Feris, F., Hurtado, M. D., & Acosta, A. (2022). Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. In JAMA Network Open (Vol. 5, Issue 9). American Medical Association (AMA). https://doi.org/10.1001/jamanetworkopen.2022.31982
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jdar, E., Kandler, K., Rigas, G., Wadden, T. A., & Wharton, S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. In Nature Medicine (Vol. 28, Issue 10, pp. 2083–2091). Springer Science and Business Media LLC. https://doi.org/10.1038/s41591-022-02026-4
Ghusn, W., Anazco, D., Fansa, S., Tama, E., Cifuentes, L., Gala, K., Calderon, G., Collazo-Clavell, M. L., Hurtado, M. D., & Acosta, A. (2024). Weight loss outcomes with semaglutide based on diabetes severity using the individualized metabolic surgery score. In eClinicalMedicine (Vol. 72, p. 102625). Elsevier BV. https://doi.org/10.1016/j.eclinm.2024.102625
Strathe, A., Horn, D. B., Larsen, M. S., Rubino, D., Srrig, R., Tran, M. T. D., Wharton, S., & Overgaard, R. V. (2023). A model‐based approach to predict individual weight loss with semaglutide in people with overweight or obesity. In Diabetes, Obesity and Metabolism (Vol. 25, Issue 11, pp. 3171–3180). Wiley. https://doi.org/10.1111/dom.15211
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.